The application of lag times in cancer pharmacoepidemiology: a narrative review

With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importance in such studies is the application of lag times. In this...

Full description

Saved in:
Bibliographic Details
Published in:Annals of epidemiology 2023-08, Vol.84, p.25-32
Main Authors: Hicks, Blánaid, Kaye, James A., Azoulay, Laurent, Kristensen, Kasper Bruun, Habel, Laurel A., Pottegård, Anton
Format: Article
Language:English
Subjects:
Bias
Cancer
Humans
Induction period
Lag time
Latency
Neoplasms
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - epidemiology
Pharmacoepidemiology
Pharmacoepidemiology - methods
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3
cites cdi_FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3
container_end_page 32
container_issue
container_start_page 25
container_title Annals of epidemiology
container_volume 84
creator Hicks, Blánaid
Kaye, James A.
Azoulay, Laurent
Kristensen, Kasper Bruun
Habel, Laurel A.
Pottegård, Anton
description With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importance in such studies is the application of lag times. In this narrative review, we discuss the main reasons for using lag times. Namely, we discuss the typically long latency period of cancer concerning both tumor promoter and initiator effects and outline why cancer latency is a key consideration when choosing a lag time. We also discuss how the use of lag times can help reduce protopathic and detection bias. Finally, we present practical advice for implementing lag periods. In general, we recommend that researchers consider the information that generated the hypothesis as well as clinical and biological knowledge to inform lag period selection. In addition, given that latency periods are usually unknown, we also advocate that researchers examine multiple lag periods in sensitivity analyses as well as duration analyses and flexible modeling approaches.
doi_str_mv 10.1016/j.annepidem.2023.05.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2813560015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S104727972300090X</els_id><sourcerecordid>2813560015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3</originalsourceid><addsrcrecordid>eNqFkMtu1TAQhi0EoqXwCuAlm4TxLXbYVRU3qRIsytqaOHNaHyVxsHNa9W14Fp4MV6d0y2pm8f3zaz7G3gloBYjuw77FZaE1jjS3EqRqwbQA-hk7Fc6qRhpnntcdtG2k7e0Je1XKHgCss_IlO1FWdD1oOGU_rm7oz29c1ykG3GJaeNrxCa_5FmcqPC484BIo8_UG84whHUtjmtL1_UeOfMGca_CWeKbbSHev2YsdToXePM4z9vPzp6uLr83l9y_fLs4vm6BdtzVCDApBaQhGoO6101a50TkcBZHSphPjIJXZWUHGoLWDRNH3KmjQ1Esc1Bl7f7y75vTrQGXzcyyBpgkXSofipRPKdADCVNQe0ZBTKZl2fs1xxnzvBfgHnX7vn3T6B50ejK86a_LtY8lhmGl8yv3zV4HzI0D11fp-9iVEqsLGmClsfkzxvyV_AWH7ivE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813560015</pqid></control><display><type>article</type><title>The application of lag times in cancer pharmacoepidemiology: a narrative review</title><source>Elsevier</source><creator>Hicks, Blánaid ; Kaye, James A. ; Azoulay, Laurent ; Kristensen, Kasper Bruun ; Habel, Laurel A. ; Pottegård, Anton</creator><creatorcontrib>Hicks, Blánaid ; Kaye, James A. ; Azoulay, Laurent ; Kristensen, Kasper Bruun ; Habel, Laurel A. ; Pottegård, Anton</creatorcontrib><description>With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importance in such studies is the application of lag times. In this narrative review, we discuss the main reasons for using lag times. Namely, we discuss the typically long latency period of cancer concerning both tumor promoter and initiator effects and outline why cancer latency is a key consideration when choosing a lag time. We also discuss how the use of lag times can help reduce protopathic and detection bias. Finally, we present practical advice for implementing lag periods. In general, we recommend that researchers consider the information that generated the hypothesis as well as clinical and biological knowledge to inform lag period selection. In addition, given that latency periods are usually unknown, we also advocate that researchers examine multiple lag periods in sensitivity analyses as well as duration analyses and flexible modeling approaches.</description><identifier>ISSN: 1047-2797</identifier><identifier>EISSN: 1873-2585</identifier><identifier>DOI: 10.1016/j.annepidem.2023.05.004</identifier><identifier>PMID: 37169040</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Bias ; Cancer ; Humans ; Induction period ; Lag time ; Latency ; Neoplasms ; Neoplasms - diagnosis ; Neoplasms - drug therapy ; Neoplasms - epidemiology ; Pharmacoepidemiology ; Pharmacoepidemiology - methods ; Time Factors</subject><ispartof>Annals of epidemiology, 2023-08, Vol.84, p.25-32</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3</citedby><cites>FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3</cites><orcidid>0000-0002-5730-9469</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37169040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hicks, Blánaid</creatorcontrib><creatorcontrib>Kaye, James A.</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><creatorcontrib>Kristensen, Kasper Bruun</creatorcontrib><creatorcontrib>Habel, Laurel A.</creatorcontrib><creatorcontrib>Pottegård, Anton</creatorcontrib><title>The application of lag times in cancer pharmacoepidemiology: a narrative review</title><title>Annals of epidemiology</title><addtitle>Ann Epidemiol</addtitle><description>With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importance in such studies is the application of lag times. In this narrative review, we discuss the main reasons for using lag times. Namely, we discuss the typically long latency period of cancer concerning both tumor promoter and initiator effects and outline why cancer latency is a key consideration when choosing a lag time. We also discuss how the use of lag times can help reduce protopathic and detection bias. Finally, we present practical advice for implementing lag periods. In general, we recommend that researchers consider the information that generated the hypothesis as well as clinical and biological knowledge to inform lag period selection. In addition, given that latency periods are usually unknown, we also advocate that researchers examine multiple lag periods in sensitivity analyses as well as duration analyses and flexible modeling approaches.</description><subject>Bias</subject><subject>Cancer</subject><subject>Humans</subject><subject>Induction period</subject><subject>Lag time</subject><subject>Latency</subject><subject>Neoplasms</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - epidemiology</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacoepidemiology - methods</subject><subject>Time Factors</subject><issn>1047-2797</issn><issn>1873-2585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkMtu1TAQhi0EoqXwCuAlm4TxLXbYVRU3qRIsytqaOHNaHyVxsHNa9W14Fp4MV6d0y2pm8f3zaz7G3gloBYjuw77FZaE1jjS3EqRqwbQA-hk7Fc6qRhpnntcdtG2k7e0Je1XKHgCss_IlO1FWdD1oOGU_rm7oz29c1ykG3GJaeNrxCa_5FmcqPC484BIo8_UG84whHUtjmtL1_UeOfMGca_CWeKbbSHev2YsdToXePM4z9vPzp6uLr83l9y_fLs4vm6BdtzVCDApBaQhGoO6101a50TkcBZHSphPjIJXZWUHGoLWDRNH3KmjQ1Esc1Bl7f7y75vTrQGXzcyyBpgkXSofipRPKdADCVNQe0ZBTKZl2fs1xxnzvBfgHnX7vn3T6B50ejK86a_LtY8lhmGl8yv3zV4HzI0D11fp-9iVEqsLGmClsfkzxvyV_AWH7ivE</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Hicks, Blánaid</creator><creator>Kaye, James A.</creator><creator>Azoulay, Laurent</creator><creator>Kristensen, Kasper Bruun</creator><creator>Habel, Laurel A.</creator><creator>Pottegård, Anton</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5730-9469</orcidid></search><sort><creationdate>202308</creationdate><title>The application of lag times in cancer pharmacoepidemiology: a narrative review</title><author>Hicks, Blánaid ; Kaye, James A. ; Azoulay, Laurent ; Kristensen, Kasper Bruun ; Habel, Laurel A. ; Pottegård, Anton</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bias</topic><topic>Cancer</topic><topic>Humans</topic><topic>Induction period</topic><topic>Lag time</topic><topic>Latency</topic><topic>Neoplasms</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - epidemiology</topic><topic>Pharmacoepidemiology</topic><topic>Pharmacoepidemiology - methods</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hicks, Blánaid</creatorcontrib><creatorcontrib>Kaye, James A.</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><creatorcontrib>Kristensen, Kasper Bruun</creatorcontrib><creatorcontrib>Habel, Laurel A.</creatorcontrib><creatorcontrib>Pottegård, Anton</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hicks, Blánaid</au><au>Kaye, James A.</au><au>Azoulay, Laurent</au><au>Kristensen, Kasper Bruun</au><au>Habel, Laurel A.</au><au>Pottegård, Anton</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The application of lag times in cancer pharmacoepidemiology: a narrative review</atitle><jtitle>Annals of epidemiology</jtitle><addtitle>Ann Epidemiol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>84</volume><spage>25</spage><epage>32</epage><pages>25-32</pages><issn>1047-2797</issn><eissn>1873-2585</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importance in such studies is the application of lag times. In this narrative review, we discuss the main reasons for using lag times. Namely, we discuss the typically long latency period of cancer concerning both tumor promoter and initiator effects and outline why cancer latency is a key consideration when choosing a lag time. We also discuss how the use of lag times can help reduce protopathic and detection bias. Finally, we present practical advice for implementing lag periods. In general, we recommend that researchers consider the information that generated the hypothesis as well as clinical and biological knowledge to inform lag period selection. In addition, given that latency periods are usually unknown, we also advocate that researchers examine multiple lag periods in sensitivity analyses as well as duration analyses and flexible modeling approaches.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37169040</pmid><doi>10.1016/j.annepidem.2023.05.004</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5730-9469</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1047-2797
ispartof Annals of epidemiology, 2023-08, Vol.84, p.25-32
issn 1047-2797
1873-2585
language eng
recordid cdi_proquest_miscellaneous_2813560015
source Elsevier
subjects Bias
Cancer
Humans
Induction period
Lag time
Latency
Neoplasms
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - epidemiology
Pharmacoepidemiology
Pharmacoepidemiology - methods
Time Factors
title The application of lag times in cancer pharmacoepidemiology: a narrative review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T12%3A51%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%C2%A0application%20of%20lag%20times%20in%20cancer%20pharmacoepidemiology:%20a%20narrative%20review&rft.jtitle=Annals%20of%20epidemiology&rft.au=Hicks,%20Bl%C3%A1naid&rft.date=2023-08&rft.volume=84&rft.spage=25&rft.epage=32&rft.pages=25-32&rft.issn=1047-2797&rft.eissn=1873-2585&rft_id=info:doi/10.1016/j.annepidem.2023.05.004&rft_dat=%3Cproquest_cross%3E2813560015%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c486t-11b3a0340c51a49484738d88ad1ee34561db235f71e55a77b2a1993c404e92ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2813560015&rft_id=info:pmid/37169040&rfr_iscdi=true